Chinook Therapeutics Inc
Chinook Therapeutics Inc logo
KDNY

Chinook Therapeutics Inc (KDNY)

$18.651.86%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$18.175
Day's Range
$18.75
$10.48
52-Week Range
$19.59
1 month return11.78%
3 month return16.77%
1 year return23.22%
5 year return71.05%

Company Information

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.
OrganizationChinook Therapeutics Inc
Employees105
CEOStephen Isaacs
IndustryHealth Technology

Analyst Recommendation

based on 14 analysts ratings

Buy
92%
Buy
7%
Hold
0%
Sell

Based on 14 Wall street analysts offering stock ratings for Chinook Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 50.13%

Current

$18.65

Target

$28.0

Recommendation Trend

Based on 14 analyst

Current1M Ago3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
796.7M
Book Value
8.28
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-2.26
Wall Street Target Price
31.43

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
15.43
Price/Book (mrq)
1.76
Enterprise Value
558.8M
Enterprise Value/Revenue
10.82
Enterprise Value/Ebitda
0.0

Technicals

50 Day MA
14.33
200 Day MA
13.8

Institutional Holdings

Samsara BioCapital, LLC

7.45%

Deep Track Capital, LP

4.87%

BlackRock Inc

4.85%

FRAZIER MANAGEMENT LLC

3.85%

Baker Bros Advisors LP

3.79%

Vanguard Group Inc

2.97%

Discover more

Frequently Asked Questions

What is Chinook Therapeutics Inc share price today?

Can Indians buy Chinook Therapeutics Inc shares?

How can I buy Chinook Therapeutics Inc shares from India?

Can Fractional shares of Chinook Therapeutics Inc be purchased?

What are the documents required to start investing in Chinook Therapeutics Inc stocks?

What are today’s High and Low prices of Chinook Therapeutics Inc?

What are today’s traded volumes of Chinook Therapeutics Inc?

What is today’s market capitalisation of Chinook Therapeutics Inc?

What is the 52 Week High and Low Range of Chinook Therapeutics Inc?

How much percentage Chinook Therapeutics Inc is down from its 52 Week High?

How much percentage Chinook Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Chinook Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Chinook Therapeutics Inc?